- Advanced search
- Guide to IMMUNOPHARMACOLOGY Portal
Ligand id: 8091
View more information in the IUPHAR Pharmacology Education Project: reslizumab
|No information available.|
|Summary of Clinical Use|
|A Phase III clinical trial of reslizumab as a treatment for eosinophilic asthma (NCT01287039) has been completed, and results are published in .
In March 2016, the US FDA approved reslizumab for use with other asthma medicines for the maintenance treatment of severe asthma in adult patients.
|Mechanism Of Action and Pharmacodynamic Effects|
|Reslizumab neutralises the effect of IL-5, a cytokine key to the activation of eosinophils. Eosinophils are the primary IL-5Rα-expressing cells. Elevated eosinophil numbers and IL-5 levels are observed in allergic rhinitis and asthma . Reslizumab reduces severe asthma attacks by reducing the levels of circulating eosinophils.|
For extended ADME data see the following:
Electronic Medicines Compendium (eMC)
European Medicines Agency (EMA)